NorthWest Biotherapeutics Inc (NWBO)

[VikingInvest]

Gary,

The amount I am speaking of is for exclusivity for certain indications, maybe even all, not to run trials. The value it will have to a company with a checkpoint inhibitor (Keytruda) is in the 100's of billions. They would then have to run trials in whatever format required to show DCVax-L works with their product in all the indications they need it for. This will extend the patent life for their product. Any other BP, who does not get exclusive rights will be left in the cold. Hence the value in gambling with a decent upfront amount to secure this exclusivity.